Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T20:18:12.937Z.
Calculation as of: 2026-10-06T20:18:12.937Z.
Quote observation: 2026-10-06T19:59:57.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 79d0a2820bd4cbdc8dee1371cb6304dc007cf4c401fb8f8a9623f82368031b99
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$1.81M
EV/FCF Ratio
N/A
TTM Avg
69.66x
3Y Avg
69.66x
5Y Avg
69.66x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TransCode Therapeutics, Inc. (RNAZ) | $1.92M | N/A | N/A | N/A | N/A |
| Autonomix Medical, Inc. (AMIX)vs › | $1.88M | N/A | N/A | N/A | N/A |
| Tenon Medical, Inc. (TNON)vs › | $1.84M | N/A | N/A | N/A | N/A |
| Beyond Air, Inc. (XAIR)vs › | $1.84M | N/A | 72.16x | 72.16x | 72.16x |
| Profusa, Inc. Common Stock (PFSA)vs › | $1.83M | N/A | N/A | N/A | N/A |
| Alaunos Therapeutics, Inc. (TCRT)vs › | $1.81M | N/A | 69.66x | 69.66x | 69.66x |
| GeoVax Labs, Inc. (GOVX)vs › | $2.13M | N/A | N/A | N/A | N/A |
| Vivos Therapeutics, Inc. (VVOS)vs › | $2.14M | N/A | N/A | N/A | N/A |
| Silo Pharma, Inc. (SILO)vs › | $1.64M | N/A | N/A | N/A | N/A |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.32M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
